STOCK TITAN
  1. Home
  2. News
  3. RSPI

RESPIRERX PHARMA INC - $RSPI STOCK NEWS

Welcome to our dedicated page for RESPIRERX PHARMA news (Ticker: $RSPI), a resource for investors and traders seeking the latest updates and insights on RESPIRERX PHARMA stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RESPIRERX PHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RESPIRERX PHARMA's position in the market.

News
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
Rhea-AI Summary
RespireRx Pharmaceuticals Inc. announces positive results from a research article on CX1739's ability to restore bladder function in rodents with spinal cord injury. The study highlights the potential of this AMPAkine to address neurogenic bladder dysfunction, improving patients' quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
clinical trial
-
News
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
Rhea-AI Summary
RespireRx Pharmaceuticals Inc. announces the advancement of KRM-II-81, a GABAA receptor potentiator, within the NIH HEAL Initiative's Preclinical Screening Platform for Pain program. The compound shows promising results in blocking pain-like behaviors in rats without detectable side effects, supporting its efficacy in various pain models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
-
News
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
Rhea-AI Summary
RespireRx Pharmaceuticals Inc. appoints Dr. Dariusz Nasiek MD, MBA to its board of directors. Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. He brings considerable value with his clinical experience in the areas in which RespireRx is developing its compounds for the treatment of respiratory disorders and spinal injury with the AMPAkine platform, and the development of GABAkines for use as non-narcotic analgesics and for treatment-resistant epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.85%
Tags
management
News
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
Rhea-AI Summary
RespireRx Pharmaceuticals Inc. (RSPI) reports successful suppression of epileptiform activity in a 19-year-old patient with pharmaco-resistant epilepsy using KRM-II-81, a novel GABAkine. The findings, published in Heliyon, Cell Press's peer-reviewed journal, suggest potential success in reducing seizure burden in pharmaco-resistant patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
News
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
Rhea-AI Summary
RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) has announced an agreement with Ponto Ventures LLC for Will Clodfelter to serve as Senior Vice President of Business Development on a part-time basis. Mr. Clodfelter will lead business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company. He has extensive experience in business development, strategy, and valuation consulting services to pharmaceutical, biotech, and medical device companies, with over 30 international and domestic pharmaceutical licensing and device negotiations. Mr. Clodfelter previously held positions at Eli Lilly and Co. and Amylin Pharmaceuticals, and was the Chief Executive Officer of Medicus Biosciences and Abvance Therapeutics, both biotechnology firms based in California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
none
-
News
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
Rhea-AI Summary
RespireRx and ResolutionRx announce partnership with Ab Initio Pharma for manufacturing and testing therapeutic drugs based on lipid nanoparticle technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
-
News
ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs
Rhea-AI Summary
RespireRx and ResolutionRx have entered into a Letter of Intent with Cantheon Capital for an aggregate investment of $3,125,000 in Australian Series A Preference Shares. The investment will support clinical trial research and development over a two and a half year period. The Series A Shares are convertible and subject to a mandatory and automatic conversion feature. RespireRx expects to incur R&D costs of approximately $16,530,571. The Ordinary Shares will be listed for trading on the Australian Securities Exchange within eighteen months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
none
-
News
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.24%
Tags
none
News
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
none
Stock RSPI logo
RESPIRERX PHARMA INC

OTC:RSPI

RSPI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RSPI Stock Data

424.57k
353.99M
6.63%
0.6%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Glen Rock